Besides scaling up through expansion, how does the leading CRO grow?

WuXi AppTec Continues Expanding Production with an Additional 500 Tons/Year of R&D Pilot Production Capacity

Recently, leading CRO WuXi AppTec, after investing 5.5 billion RMB in domestic expansion against the trend, plans to further increase its capacity. The company's subsidiary, Changzhou STA Pharmaceutical Co., Ltd., has entered the environmental impact assessment approval stage for a project to build and expand a 470-ton/year new drug R&D pilot platform and a 30-ton/year new drug R&D center. This marks another step toward the start of construction.

According to GateView, the expansion project will be located at the existing site at 589 Yulong North Road, Xinbei District, Changzhou, Jiangsu Province. It will utilize existing workshops, storage facilities, and utility auxiliary facilities, adding approximately 228 main and auxiliary equipment sets, including spray dryers, purification columns, and high-level tanks. This will increase the R&D pilot service capacity by 470 tons/year, including:

• 80 tons/year for new anti-tumor drugs
• 80 tons/year for new antiviral drugs
• 120 tons/year for new anti-diabetic drugs
• 70 tons/year for new immune system drugs
• 60 tons/year for new anti-infective drugs
• 60 tons/year for new cardiovascular drugs

Additionally, around 14 sets of main and auxiliary equipment, including reactors, storage tanks, and receiving tanks, will be added, increasing the R&D pilot service capacity by 30 tons/year, with:

• 10 tons/year for new anti-tumor drugs
• 10 tons/year for new anti-diabetic drugs
• 10 tons/year for new cardiovascular drugs

Image source: Hequan Pharmaceuticals

WuXi AppTec continues to expand its scale. In May, the construction of a new R&D and production base in Singapore's Tuas Biomedical Park, with an investment of 2 billion SGD, officially began. This base will feature seven production workshops providing API R&D and production services for small molecules, oligonucleotides, peptides, and complex synthetic conjugates, expected to be operational by 2027.

Domestically, in January of this year, WuXi completed the expansion of peptide production workshops at its Changzhou and Taixing production bases, increasing total capacity to 32,000 liters.

In July, WuXi's subsidiary Taixing STA Pharmaceutical Co., Ltd. invested 5.5 billion RMB in counter-cyclical expansion, focusing on pilot research in anti-tumor, antiviral, diabetes, immune system, anti-infective, cardiovascular, and animal protection drugs. Upon completion, the project will provide 750 tons/year of special/patented API R&D capacity, bringing the combined R&D pilot capacity of ongoing projects to 878 tons/year.

In August, the company plans to add another 500 tons/year of R&D pilot production capacity at the Changzhou site, targeting the same therapeutic areas: anti-tumor, antiviral, diabetes, immune system, anti-infective, and cardiovascular drugs.

Image source: Hequan Pharmaceuticals

Regarding overseas expansion, industry media comment that in the current geopolitical climate, WuXi's leader Li Ge aims to make WuXi AppTec more "international." This reflects his understanding of the new landscape and serves as the foundation of WuXi's business model for the next decade. A broad layout of overseas capacity acts as a "fallback," maximizing the ability to balance regulatory uncertainties in various countries.

Despite frequent domestic expansion, WuXi's long-term capacity layout focus will likely remain in China. The advantages of the domestic industrial chain, engineer talent pool, cost efficiency, and delivery timeliness will continue to support WuXi's participation in international competition. Additionally, the importance of the domestic market for WuXi and its major multinational pharmaceutical clients is growing, as evidenced by the increasing clinical trial activity in China across various therapeutic areas, from oncology to autoimmune diseases.

"Prime Territory" for CXOs and WuXi AppTec's "Three Growth Secrets"

WuXi AppTec's mid-2024 report, released last week, highlighted multiple positive signals, injecting strong momentum into the CXO (Contract Research, Development, and Manufacturing Organization) industry. The company has been praised by industry media as a "prime territory for CXOs." Indeed, this seems accurate. WuXi's annual revenue, which reaches 40 billion RMB, is equivalent to the combined total of several leading companies. Globally, it is one of the few companies consistently outperforming its revenue in terms of profitability. Industry analysts attribute WuXi's success to three major growth secrets:

1. Business Model: WuXi AppTec operates as a global end-to-end integrated CRDMO. A Morgan Stanley survey of representatives from 108 pharmaceutical companies primarily from Europe, the US, and Japan found that pharmaceutical companies prioritize end-to-end integrated service capabilities when choosing a CXO partner. WuXi’s comprehensive service, spanning from compound screening for drug discovery to preclinical animal studies, human clinical trials, and commercial production, allows it to support clients throughout the entire process. This exceptional "do-it-all" capability makes WuXi indispensable, resulting in strong customer loyalty. The top 10 clients have a 100% retention rate, and clients using services from multiple departments contribute 93% of total revenue.

2. Economies of Scale and Industry Barriers: Stable clients highly value WuXi AppTec’s diverse horizontal business lines. The first-quarter report indicates that clients collaborating with multiple departments generated 7.2 billion RMB in revenue, accounting for over 90% of total revenue. Continuous expansion in more specialized areas like peptides and oligonucleotides further amplifies WuXi’s scale advantage.

3. Lean Management for Operational Efficiency: WuXi consistently enhances its operational efficiency through lean management, maintaining high profitability and stable cash flow. CEO Li Ge revealed that the company expects to achieve free cash flow of 4 to 5 billion RMB in 2024, with net profit margins comparable to last year. Continuous optimization in cost control enables WuXi to maintain competitive pricing, avoiding the pitfalls of industry "price wars." The mid-year report shows a Non-IFRS gross margin of 39.8% for the second quarter, up from 38.7% in the first quarter, indicating further margin improvement.

Key Takeaways for CXO Breakthroughs:

1. Scaling Up: While not necessarily large in every aspect, CXOs should establish their technical moat and scale advantage in specific niches. Expanding into end-to-end integrated services, as seen with WuXi AppTec's CRDMO model, can mitigate the risk of order downturns during industry downcycles.

Image source: Yumei Kangde 2024 mid-year edition

    2. Market Diversification: To mitigate geopolitical and market risks, diversification is crucial. Many domestic CXOs without overseas business currently struggle to break even and maintain basic team operations. In contrast, WuXi's scale and excellent cost control enable it to maintain pricing advantages. Overseas business ensures sufficient revenue and cash flow, allowing the team to focus on service quality rather than competing for low-priced orders.

    3. Lean Management: Controlling costs and improving efficiency to maintain profitability and steady cash flow is a long-term task for CXOs. This allows them to adapt flexibly to industry cycles and plan strategically.